FDA Approves Ruzurgi for Children With Rare Autoimmune Disorder

TUESDAY, May 7, 2019 -- Ruzurgi (amifampridine) tablets are now approved to treat Lambert-Eaton myasthenic syndrome (LEMS) in children aged 6 to 17 years, the U.S. Food and Drug Administration announced yesterday. Ruzurgi is the first treatment to...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news